Phase I-II Study of R11577

ID Number 12-0567-00001

Principal Investigator(s)
George Raptis

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to examine the safety and effectiveness of the investigational drug, Zarnestra, when used in combination with the standard care of chemotherapy drug, Paclitaxel, in patients with locally advanced breast cancer. Zarnestra is considered an investigational drug in this research study because it has not been approved by the Food and Drug Administration (FDA).

Contact Information
Jenny Figueroa
(212) 824-7320

Recruiting Patients: No